SK282665B6 - Cyklická aminokyselina a farmaceutický prostriedok na jej báze - Google Patents

Cyklická aminokyselina a farmaceutický prostriedok na jej báze Download PDF

Info

Publication number: SK282665B6
Authority: SK; Slovakia
Prior art keywords: amino acid; cyclic amino; group; alkyl; branched
Prior art date: 1996-02-07

Application number

SK1067-98A

Other languages

English (en)

Slovak (sk)

Other versions

SK106798A3 (en

Inventor

David Christopher Horwell

Justin S. Bryans

Clare Octavia Kneen

Giles S. Ratcliffe

Original Assignee

Warner-Lambert Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-02-07

Filing date

1997-01-02

Publication date

2002-11-06

1997-01-02 Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company

1999-07-12 Publication of SK106798A3 publication Critical patent/SK106798A3/sk

2002-11-06 Publication of SK282665B6 publication Critical patent/SK282665B6/sk

Links

-1 Cyclic amino acid Chemical class 0.000 title claims abstract description 45
239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 20
125000000217 alkyl group Chemical group 0.000 claims abstract description 18
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 17
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 15
239000001257 hydrogen Substances 0.000 claims abstract description 15
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 12
150000003839 salts Chemical class 0.000 claims abstract description 11
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
229910052717 sulfur Inorganic materials 0.000 claims abstract description 7
125000001424 substituent group Chemical group 0.000 claims abstract description 6
229910052736 halogen Inorganic materials 0.000 claims abstract description 5
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 4
229910052760 oxygen Inorganic materials 0.000 claims abstract description 4
239000003937 drug carrier Substances 0.000 claims abstract description 3
150000002367 halogens Chemical class 0.000 claims abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
208000019901 Anxiety disease Diseases 0.000 claims description 7
230000036506 anxiety Effects 0.000 claims description 7
208000035475 disorder Diseases 0.000 claims description 5
206010015037 epilepsy Diseases 0.000 claims description 5
208000015122 neurodegenerative disease Diseases 0.000 claims description 5
230000036407 pain Effects 0.000 claims description 5
DMBZPJRQJHDESH-UHFFFAOYSA-N 2-[4-(aminomethyl)oxan-4-yl]acetic acid Chemical compound OC(=O)CC1(CN)CCOCC1 DMBZPJRQJHDESH-UHFFFAOYSA-N 0.000 claims description 4
BCKRPDOWCLBAJM-UHFFFAOYSA-N 2-[4-(aminomethyl)thian-4-yl]acetic acid Chemical compound OC(=O)CC1(CN)CCSCC1 BCKRPDOWCLBAJM-UHFFFAOYSA-N 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
206010010904 Convulsion Diseases 0.000 claims description 3
201000010099 disease Diseases 0.000 claims description 3
230000002981 neuropathic effect Effects 0.000 claims description 2
229910020008 S(O) Inorganic materials 0.000 abstract 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
150000001875 compounds Chemical class 0.000 description 35
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 15
239000000203 mixture Substances 0.000 description 14
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
238000000034 method Methods 0.000 description 13
238000002360 preparation method Methods 0.000 description 13
238000012360 testing method Methods 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 11
229910000041 hydrogen chloride Inorganic materials 0.000 description 11
239000004480 active ingredient Substances 0.000 description 10
239000000243 solution Substances 0.000 description 10
241000700159 Rattus Species 0.000 description 9
125000005843 halogen group Chemical group 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000003814 drug Substances 0.000 description 7
239000007787 solid Substances 0.000 description 7
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
239000002775 capsule Substances 0.000 description 6
239000003826 tablet Substances 0.000 description 6
208000006011 Stroke Diseases 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 5
229960002870 gabapentin Drugs 0.000 description 5
229960003692 gamma aminobutyric acid Drugs 0.000 description 5
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
239000007788 liquid Substances 0.000 description 5
230000036651 mood Effects 0.000 description 5
125000003884 phenylalkyl group Chemical group 0.000 description 5
239000000843 powder Substances 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
230000002490 cerebral effect Effects 0.000 description 4
150000002431 hydrogen Chemical class 0.000 description 4
238000004452 microanalysis Methods 0.000 description 4
238000010992 reflux Methods 0.000 description 4
239000002904 solvent Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 3
208000020401 Depressive disease Diseases 0.000 description 3
206010021143 Hypoxia Diseases 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229910021529 ammonia Inorganic materials 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
125000000753 cycloalkyl group Chemical group 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
235000013305 food Nutrition 0.000 description 3
230000006870 function Effects 0.000 description 3
239000007937 lozenge Substances 0.000 description 3
241001515942 marmosets Species 0.000 description 3
239000000463 material Substances 0.000 description 3
229940072228 neurontin Drugs 0.000 description 3
239000000047 product Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 2
MLIREBYILWEBDM-UHFFFAOYSA-M 2-cyanoacetate Chemical compound [O-]C(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-M 0.000 description 2
LPLLVINFLBSFRP-UHFFFAOYSA-N 2-methylamino-1-phenylpropan-1-one Chemical compound CNC(C)C(=O)C1=CC=CC=C1 LPLLVINFLBSFRP-UHFFFAOYSA-N 0.000 description 2
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000132539 Cosmos Species 0.000 description 2
235000005956 Cosmos caudatus Nutrition 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
208000006083 Hypokinesia Diseases 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
239000007868 Raney catalyst Substances 0.000 description 2
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
229910000564 Raney nickel Inorganic materials 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000001773 anti-convulsant effect Effects 0.000 description 2
230000000949 anxiolytic effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000003925 brain function Effects 0.000 description 2
208000029028 brain injury Diseases 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
229910052799 carbon Chemical group 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
239000003086 colorant Substances 0.000 description 2
150000001916 cyano esters Chemical class 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
125000004494 ethyl ester group Chemical group 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
239000007789 gas Substances 0.000 description 2
230000003483 hypokinetic effect Effects 0.000 description 2
230000007954 hypoxia Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
150000003951 lactams Chemical class 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
125000004434 sulfur atom Chemical group 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000000946 synaptic effect Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
206010059245 Angiopathy Diseases 0.000 description 1
102000005862 Angiotensin II Human genes 0.000 description 1
101800000733 Angiotensin-2 Proteins 0.000 description 1
206010002660 Anoxia Diseases 0.000 description 1
241000976983 Anoxia Species 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
108090000312 Calcium Channels Proteins 0.000 description 1
102000003922 Calcium Channels Human genes 0.000 description 1
241000288950 Callithrix jacchus Species 0.000 description 1
206010008111 Cerebral haemorrhage Diseases 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
238000006969 Curtius rearrangement reaction Methods 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
206010014498 Embolic stroke Diseases 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
206010027940 Mood altered Diseases 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
150000007945 N-acyl ureas Chemical class 0.000 description 1
206010028923 Neonatal asphyxia Diseases 0.000 description 1
208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
206010034912 Phobia Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
208000027520 Somatoform disease Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 description 1
229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 1
229960001171 acetohydroxamic acid Drugs 0.000 description 1
ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical group C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
239000000556 agonist Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
102000015007 alpha-adrenergic receptor activity proteins Human genes 0.000 description 1
108040006816 alpha-adrenergic receptor activity proteins Proteins 0.000 description 1
125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229950006323 angiotensin ii Drugs 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000007953 anoxia Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000002921 anti-spasmodic effect Effects 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
230000000338 anxiogenic effect Effects 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
235000021311 artificial sweeteners Nutrition 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
238000013172 carotid endarterectomy Methods 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000002585 cerebral angiography Methods 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000004981 cycloalkylmethyl group Chemical group 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000005286 illumination Methods 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000155 melt Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000007510 mood change Effects 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
BNZBMEIFAOYZEA-UHFFFAOYSA-N n-cyanoacetamide Chemical compound CC(=O)NC#N BNZBMEIFAOYZEA-UHFFFAOYSA-N 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
235000021096 natural sweeteners Nutrition 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
208000027753 pain disease Diseases 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
229960005152 pentetrazol Drugs 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
208000033300 perinatal asphyxia Diseases 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
208000019899 phobic disease Diseases 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
235000015277 pork Nutrition 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
210000001747 pupil Anatomy 0.000 description 1
238000003653 radioligand binding assay Methods 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical group [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000001119 stannous chloride Substances 0.000 description 1
235000011150 stannous chloride Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000012353 t test Methods 0.000 description 1
239000007885 tablet disintegrant Substances 0.000 description 1
108060008037 tachykinin Proteins 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
OVRJVKCZJCNSOW-UHFFFAOYSA-N thian-4-one Chemical compound O=C1CCSCC1 OVRJVKCZJCNSOW-UHFFFAOYSA-N 0.000 description 1
239000012485 toluene extract Substances 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 1
238000001665 trituration Methods 0.000 description 1
WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
229910052721 tungsten Inorganic materials 0.000 description 1
239000010937 tungsten Substances 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
230000006441 vascular event Effects 0.000 description 1
238000007631 vascular surgery Methods 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
239000011345 viscous material Substances 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Pyrane Compounds (AREA)

SK1067-98A 1996-02-07 1997-01-02 Cyklická aminokyselina a farmaceutický prostriedok na jej báze SK282665B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US1127896P	1996-02-07	1996-02-07
PCT/US1997/000255 WO1997029101A1 (en)	1996-02-07	1997-01-02	Novel cyclic amino acids as pharmaceutical agents

Publications (2)

Publication Number	Publication Date
SK106798A3 SK106798A3 (en)	1999-07-12
SK282665B6 true SK282665B6 (sk)	2002-11-06

Family

ID=21749660

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1067-98A SK282665B6 (sk)	1996-02-07	1997-01-02	Cyklická aminokyselina a farmaceutický prostriedok na jej báze

Country Status (22)

Country	Link
US (1)	US5929088A (es)
EP (1)	EP0888325B1 (es)
JP (1)	JP2000511877A (es)
KR (1)	KR19990082349A (es)
AT (1)	ATE218135T1 (es)
AU (1)	AU720628B2 (es)
BR (1)	BR9707366A (es)
CA (1)	CA2244708A1 (es)
CZ (1)	CZ296052B6 (es)
DE (1)	DE69712877T2 (es)
DK (1)	DK0888325T3 (es)
EA (1)	EA001534B1 (es)
ES (1)	ES2176668T3 (es)
HU (1)	HUP9901074A3 (es)
IL (1)	IL125562A (es)
NO (1)	NO983612L (es)
NZ (1)	NZ326669A (es)
PL (1)	PL328432A1 (es)
PT (1)	PT888325E (es)
SK (1)	SK282665B6 (es)
WO (1)	WO1997029101A1 (es)
ZA (1)	ZA97991B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE241351T1 (de)	1996-07-24	2003-06-15	Warner Lambert Co	Isobutylgaba und dessen derivate zur schmerzbehandlung
BR9812351A (pt) *	1997-09-18	2000-09-19	Warner Lambert Co	Novo processo estereoseletivo para a preparação de análogas gabapentinas
US6984659B2 (en)	1997-11-18	2006-01-10	Klinikum Der Albert-Ludwigs Universitaet	2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
DE19751062A1 (de) *	1997-11-18	1999-07-08	Univ Ludwigs Albert	An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels
BR9814287A (pt) *	1997-12-16	2000-10-03	Warner Lambert Co	"4(3)-aminometil-(tio)piran 4(3) substituìdo ou derivados da piperidina (= análogos da gabapentina), sua preparação e seu uso no tratamento de desordens neurológicas"
AU2001247762A1 (en) *	2000-03-28	2001-10-08	Delorenzo, Robert, J	Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death
WO2002032376A2 (en)	2000-10-06	2002-04-25	Xenoport, Inc.	Bile-acid conjugates for providing sustained systemic concentrations of drugs
EP1343805A4 (en)	2000-10-06	2005-07-20	Xenoport Inc	COMPOUNDS DERIVED FROM GALLENIC ACIDS FOR THE PROVISION OF CONTINUING SYSTEMIC CONCENTRATIONS OF MEDICINAL PRODUCTS AFTER ORAL ADMINISTRATION
GB2368579A (en) *	2000-10-31	2002-05-08	Parke Davis & Co Ltd	Azole pharmaceutical agents
EP1404324B2 (en)	2001-06-11	2011-04-06	XenoPort, Inc.	Prodrugs of gaba analogs, compositions and uses thereof
US7420002B2 (en)	2001-06-11	2008-09-02	Xenoport	Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US7186855B2 (en)	2001-06-11	2007-03-06	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en)	2001-06-11	2007-06-19	Xenoport, Inc.	Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US8048917B2 (en)	2005-04-06	2011-11-01	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en)	2001-06-11	2004-11-16	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US6927036B2 (en)	2002-02-19	2005-08-09	Xero Port, Inc.	Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US7026351B2 (en)	2002-03-20	2006-04-11	Xenoport, Inc.	Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof
WO2003099338A2 (en)	2002-05-17	2003-12-04	Xenoport, Inc.	Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US20040092498A1 (en) *	2002-08-16	2004-05-13	David Blakemore	Substituted glycine derivatives for use as medicaments
AU2003297927A1 (en)	2002-12-11	2004-06-30	Xenoport, Inc.	Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
DE60332387D1 (de)	2002-12-13	2010-06-10	Warner Lambert Co	Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
CA2451267A1 (en)	2002-12-13	2004-06-13	Warner-Lambert Company Llc	Pharmaceutical uses for alpha2delta ligands
MXPA06002731A (es)	2003-09-11	2006-06-05	Xenoport Inc	Tratamiento y/o prevencion de incontinencia urinaria utilizando profarmacos de analogos de gaba.
CA2537402C (en)	2003-09-12	2009-05-05	Pfizer Inc.	Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
CA2538802C (en)	2003-09-17	2015-01-27	Xenoport, Inc.	Treating or preventing restless legs syndrome using prodrugs of gaba analogs
PT1677767E (pt)	2003-10-14	2011-10-13	Xenoport Inc	Forma cristalina de análogo de ácido gama-aminobutírico
EP2343073A3 (en)	2003-12-11	2011-10-12	Sepracor Inc.	Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
BRPI0517227B8 (pt)	2004-11-04	2021-05-25	Xenoport Inc	comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido
PT2125021E (pt)	2006-12-22	2011-07-26	Recordati Ireland Ltd	Terapia de combinação de distúrbios do tracto urinário inferior com 2 ligandos e nsaid
WO2009024615A1 (en) *	2007-08-23	2009-02-26	Novartis Ag	Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors
EP2250148B1 (en)	2008-01-25	2016-08-17	XenoPort, Inc.	Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
US7868043B2 (en)	2008-01-25	2011-01-11	Xenoport, Inc.	Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
CA2710538A1 (en)	2008-01-25	2009-07-30	Xenoport, Inc.	Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
ES2589915T3 (es)	2008-10-08	2016-11-17	Xgene Pharmaceutical Inc	Conjugados de GABA y métodos de utilización de los mismos
WO2010084797A1 (ja) *	2009-01-21	2010-07-29	第一三共株式会社	含ヘテロ原子化合物
US9066853B2 (en)	2013-01-15	2015-06-30	Warsaw Orthopedic, Inc.	Clonidine compounds in a biodegradable fiber
HUE047629T2 (hu)	2013-01-28	2020-05-28	Lopez Hector L	Eljárások ß-alanin tolerancia, farmakodinamika és hatékonyság javítására és azok alkalmazása
WO2019219000A1 (en)	2018-05-14	2019-11-21	Xgene Pharmaceutical Inc.	Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4087544A (en) *	1974-12-21	1978-05-02	Warner-Lambert Company	Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) *	1974-12-21	1982-09-23	Gödecke AG, 1000 Berlin	1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US5270317A (en) *	1990-03-20	1993-12-14	Elf Sanofi	N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
KR970010173B1 (ko) *	1991-07-09	1997-06-21	닛뽕소다 가부시끼가이샤	함헤테로 시클로헥산디온 유도체, 그의 제조방법 및 제초제
US5514801A (en) *	1992-12-29	1996-05-07	Monsanto Company	Cyclic sulfone containing retroviral protease inhibitors
GB9314758D0 (en) *	1993-07-16	1993-08-25	Wyeth John & Brother Ltd	Heterocyclic derivatives
US5527194A (en) *	1994-02-02	1996-06-18	Brunswick Corporation	Thrust sensor for marine drives
US5491152A (en) *	1994-03-23	1996-02-13	The Du Pont Merck Pharmaceutical Company	Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis
US5760006A (en) *	1997-06-23	1998-06-02	Ortho Pharmaceutical Corporation	Anticonvulsant derivatives useful in treating psoriasis

1997
- 1997-01-02 HU HU9901074A patent/HUP9901074A3/hu unknown
- 1997-01-02 NZ NZ326669A patent/NZ326669A/en unknown
- 1997-01-02 BR BR9707366A patent/BR9707366A/pt not_active Application Discontinuation
- 1997-01-02 WO PCT/US1997/000255 patent/WO1997029101A1/en not_active Ceased
- 1997-01-02 PT PT97901385T patent/PT888325E/pt unknown
- 1997-01-02 CA CA002244708A patent/CA2244708A1/en not_active Abandoned
- 1997-01-02 SK SK1067-98A patent/SK282665B6/sk unknown
- 1997-01-02 CZ CZ19982452A patent/CZ296052B6/cs not_active IP Right Cessation
- 1997-01-02 ES ES97901385T patent/ES2176668T3/es not_active Expired - Lifetime
- 1997-01-02 DE DE69712877T patent/DE69712877T2/de not_active Expired - Fee Related
- 1997-01-02 KR KR1019980706079A patent/KR19990082349A/ko not_active Ceased
- 1997-01-02 AU AU15295/97A patent/AU720628B2/en not_active Ceased
- 1997-01-02 EP EP97901385A patent/EP0888325B1/en not_active Expired - Lifetime
- 1997-01-02 US US09/077,053 patent/US5929088A/en not_active Expired - Fee Related
- 1997-01-02 AT AT97901385T patent/ATE218135T1/de not_active IP Right Cessation
- 1997-01-02 IL IL12556297A patent/IL125562A/en not_active IP Right Cessation
- 1997-01-02 JP JP09528505A patent/JP2000511877A/ja not_active Abandoned
- 1997-01-02 DK DK97901385T patent/DK0888325T3/da active
- 1997-01-02 EA EA199800682A patent/EA001534B1/ru not_active IP Right Cessation
- 1997-01-02 PL PL97328432A patent/PL328432A1/xx unknown
- 1997-02-06 ZA ZA9700991A patent/ZA97991B/xx unknown
1998
- 1998-08-06 NO NO983612A patent/NO983612L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
PL328432A1 (en)	1999-02-01
BR9707366A (pt)	1999-07-20
DE69712877T2 (de)	2002-11-14
EA001534B1 (ru)	2001-04-23
SK106798A3 (en)	1999-07-12
CA2244708A1 (en)	1997-08-14
AU720628B2 (en)	2000-06-08
WO1997029101A1 (en)	1997-08-14
HUP9901074A3 (en)	2001-08-28
EP0888325A1 (en)	1999-01-07
DK0888325T3 (da)	2002-09-16
NO983612L (no)	1998-10-06
EA199800682A1 (ru)	1999-02-25
ZA97991B (en)	1997-08-15
IL125562A (en)	2001-08-08
AU1529597A (en)	1997-08-28
KR19990082349A (ko)	1999-11-25
ES2176668T3 (es)	2002-12-01
US5929088A (en)	1999-07-27
IL125562A0 (en)	1999-03-12
JP2000511877A (ja)	2000-09-12
DE69712877D1 (de)	2002-07-04
HUP9901074A2 (hu)	2001-04-28
ATE218135T1 (de)	2002-06-15
NO983612D0 (no)	1998-08-06
CZ245298A3 (cs)	1998-11-11
EP0888325B1 (en)	2002-05-29
CZ296052B6 (cs)	2005-12-14
NZ326669A (en)	2001-05-25
PT888325E (pt)	2002-10-31

Publication	Publication Date	Title
SK282665B6 (sk)	2002-11-06	Cyklická aminokyselina a farmaceutický prostriedok na jej báze
AU731279B2 (en)	2001-03-29	Novel bridged cyclic amino acids as pharmaceutical agents
CZ293759B6 (cs)	2004-07-14	Substituovaná cyklická aminokyselina, její použití a farmaceutický prostředek na její bázi
US6518289B1 (en)	2003-02-11	1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
HRP970560A2 (en)	1998-08-31	Substituted gamma aminobutyric acids as pharmaceutical agents
CZ295960B6 (cs)	2005-12-14	Bicyklická aminokyselina, její použití a farmaceutická kompozice s jejím obsahem
CA2245647C (en)	2006-03-21	Novel bridged cyclic amino acids as pharmaceutical agents
MXPA99001776A (es)	1999-06-01	Acidos aminobutiricos gama substituidos como agentes farmaceuticos